Revenue from Contract with Customer, Excluding Assessed Tax in USD of Pacira BioSciences, Inc. from 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Pacira BioSciences, Inc. quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from 2016 to Q3 2025.
  • Pacira BioSciences, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending September 30, 2025 was $180M, a 6.49% increase year-over-year.
  • Pacira BioSciences, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $675M, a 1.22% increase from 2022.
  • Pacira BioSciences, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $667M, a 23.1% increase from 2021.
  • Pacira BioSciences, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $542M, a 26% increase from 2020.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Growth (%)

Pacira BioSciences, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $180M +$10.9M +6.49% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $181M +$3.08M +1.73% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 $169M +$1.81M +1.08% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q3 2024 $695M $169M +$4.65M +2.84% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 $690M $178M +$8.56M +5.05% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 $682M $167M +$6.78M +4.23% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $675M $181M +$9.29M +5.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $666M $164M -$3.54M -2.11% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $669M $169M +$56K +0.03% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-30
Q1 2023 $669M $160M +$2.35M +1.49% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $667M $172M +$12.8M +8.02% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $654M $167M +$39.7M +31.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $614M $169M +$33.8M +24.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $580M $158M +$39M +32.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $542M $159M +$28.2M +21.5% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 $513M $128M +$10.2M +8.71% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $503M $136M +$60.1M +79.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $443M $119M +$13.3M +12.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $430M $131M +$9.13M +7.49% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $421M $117M +$13.1M +12.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $407M $75.5M -$26.3M -25.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $434M $106M +$14.8M +16.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $419M $122M +$27.1M +28.6% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $392M $104M +$21.6M +26.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-30
Q2 2019 $370M $102M +$21.1M +26.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $349M $90.9M +$16.6M +22.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $332M $94.7M +$15.9M +20.2% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 $317M $82.7M +$15.8M +23.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $301M $80.7M +$10.6M +15.1% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $290M $74.3M +$5.86M +8.57% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $284M $78.8M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-21
Q3 2017 $67M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 $70.1M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $68.4M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03

Pacira BioSciences, Inc. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $675M +$8.16M +1.22% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-29
2022 $667M +$125M +23.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-29
2021 $542M +$112M +26% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-29
2020 $430M +$10.7M +2.56% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $419M +$86.5M +26% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $332M +$48.1M +16.9% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-01
2017 $284M +$14.3M +5.28% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-21
2016 $270M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.